ImmunityBio Inc. (IBRX) is set to bring smile on the investors face as Analysts sets mean Target price of $10.00 – Invest Chronicle
Home  »  Industry   »  ImmunityBio Inc. (IBRX) is set to bring smile on t...

ImmunityBio Inc. (IBRX) is set to bring smile on the investors face as Analysts sets mean Target price of $10.00

At the end of the latest market close, ImmunityBio Inc. (IBRX) was valued at $3.29. In that particular session, Stock kicked-off at the price of $3.19 while reaching the peak value of $3.73 and lowest value recorded on the day was $3.15. The stock current value is $3.58.Recently in News on June 6, 2022, ImmunityBio Announces QUILT Trial Results for BCG-Unresponsive Bladder Cancer and Advanced Metastatic Pancreatic Cancer at the 2022 American Society of Clinical Oncology Annual Meeting. Data from trials underscore ImmunityBio’s vision of activating NK cells and T cells to advance care in difficult-to-treat cancers. You can read further details here

ImmunityBio Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $7.85 on 02/17/22, with the lowest value was $2.60 for the same time period, recorded on 05/12/22.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


ImmunityBio Inc. (IBRX) full year performance was -73.79%

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, ImmunityBio Inc. shares are logging -77.12% during the 52-week period from high price, and 37.69% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $2.60 and $15.65.

The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 1592362 for the day, which was evidently lower, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the ImmunityBio Inc. (IBRX) recorded performance in the market was -41.12%, having the revenues showcasing -40.73% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 1.33B, as it employees total of 688 workers.

Market experts do have their say about ImmunityBio Inc. (IBRX)

During the last month, 0 analysts gave the ImmunityBio Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.

According to the data provided on, the moving average of the company in the 100-day period was set at 4.96, with a change in the price was noted -1.47. In a similar fashion, ImmunityBio Inc. posted a movement of -29.11% for the period of last 100 days, recording 1,824,995 in trading volumes.

Technical breakdown of ImmunityBio Inc. (IBRX)

Raw Stochastic average of ImmunityBio Inc. in the period of last 50 days is set at 35.90%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 42.05%. In the last 20 days, the company’s Stochastic %K was 28.79% and its Stochastic %D was recorded 21.46%.

Bearing in mind the latest performance of ImmunityBio Inc., several moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -41.12%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -44.75%, alongside a downfall of -73.79% for the period of the last 12 months. The shares increased approximately by 20.13% in the 7-day charts and went up by -8.44% in the period of the last 30 days. Common stock shares were lifted by -40.73% during last recorded quarter.

Leave a Comment

Your email address will not be published.

On Key

Related Posts